Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Update

Xilio Therapeutics, Inc. (NASDAQ:XLO) was the recipient of a large drop in short interest during the month of February. As of February 28th, there was short interest totalling 694,600 shares, a drop of 61.6% from the February 13th total of 1,810,000 shares. Based on an average daily trading volume, of 3,830,000 shares, the short-interest ratio is currently 0.2 days. Approximately 4.7% of the company’s shares are short sold.

Institutional Trading of Xilio Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Trustees of Columbia University in the City of New York acquired a new stake in shares of Xilio Therapeutics in the fourth quarter worth $238,000. Balyasny Asset Management L.P. boosted its position in Xilio Therapeutics by 26.0% during the 4th quarter. Balyasny Asset Management L.P. now owns 343,230 shares of the company’s stock worth $328,000 after purchasing an additional 70,744 shares during the period. Aptus Capital Advisors LLC purchased a new stake in Xilio Therapeutics during the 4th quarter worth $39,000. Gilead Sciences Inc. acquired a new stake in Xilio Therapeutics in the 4th quarter valued at $8,696,000. Finally, Raymond James Financial Inc. purchased a new position in Xilio Therapeutics in the fourth quarter valued at about $48,000. 54.29% of the stock is currently owned by institutional investors and hedge funds.

Xilio Therapeutics Price Performance

XLO opened at $0.80 on Friday. Xilio Therapeutics has a 12 month low of $0.58 and a 12 month high of $1.93. The business has a 50-day moving average of $0.93 and a two-hundred day moving average of $0.94. The stock has a market capitalization of $35.18 million, a price-to-earnings ratio of -0.47 and a beta of -0.38.

Xilio Therapeutics (NASDAQ:XLO) last released its earnings results on Tuesday, March 11th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.02. The company had revenue of $1.72 million during the quarter, compared to analysts’ expectations of $2.26 million. Equities research analysts anticipate that Xilio Therapeutics will post -1.14 earnings per share for the current year.

About Xilio Therapeutics

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors.